Paris-based biotech startup DNA Script raises €34.4 million in Series B funding to more efficiently synthesize DNA and accelerate research
Summary
DNA Script is a biotech company developing devices and methods to more quickly and affordably synthesize DNA using enzymes for research purposes, with potentially broad implications for the pharmaceutical, healthcare, and even agtech industries. The product portfolio based on DNA Script’s proprietary enzymatic synthesis platform will enable molecular biology researchers to accelerate their experiments – with the goal of moving from design to results within a day for a broad range of applications. Founded in 2014, the Paris-based startup has announced an oversubscribed Series B fundraising of €34.4 million led by Life Sciences Partners (LSP). “In less than two years since our last financing round, the DNA Script team has developed enzymatic synthesis technology at an incredibly fast pace and extended the company’s lead in this exciting and quickly expanding sector,” said Thomas Ybert, CEO and cofounder of DNA Script. “Our technology is now reliable enough for its first commercial applications, which we believe will deliver the promise of same-day results to researchers everywhere, with DNA synthesis that can be completed in just a few hours.”